Claim Amendments

Claims 1-11 (Cancelled)

12. (Currently Amended) An isolated human antibody or fragment thereof ~~The antibody or antibody fragment of Claim 1~~, which specifically binds to insulin-like growth factor-I receptor (IGF-IR) ~~and comprises at least one~~ comprising complementarity-determining region[[s]] (CDR[[s]]) having ~~an amino~~ the amino acid sequence ~~selected from~~ [[of]] SEQ ID NO:14 at V_HCDR1, SEQ ID NO:16 at V_HCDR2, SEQ ID NO:18 at V_HCDR3, SEQ ID NO:20 or 26 at V_LCDR1, SEQ ID NO:22 or 28 at V_LCDR2, [[and]] SEQ ID NO:24 or 30 at V_LCDR3[[.]]~~, SEQ ID NO:26 at V_LCDR1, SEQ ID NO:28 at V_LCDR2, and SEQ ID NO:30 at V_LCDR3.~~

13. (Currently Amended) The antibody or antigen binding fragment of ~~Claim 1~~ Claim 12, which comprises SEQ ID NO:14 at V_HCDR1, SEQ ID NO:16 at V_HCDR2, ~~and~~ SEQ ID NO:18 at V_HCDR3, SEQ ID NO:20 at V_LCDR1, SEQ ID NO:22 at V_LCDR2, [[and]] SEQ ID NO:24 at V_LCDR3.

14. (Currently Amended) The antibody or antigen binding fragment of ~~Claim 1~~ Claim 12, which comprises SEQ ID NO:14 at V_HCDR1, SEQ ID NO:16 at V_HCDR2, ~~and~~ SEQ ID NO:18 at V_HCDR3, SEQ ID NO:26 at V_LCDR1, SEQ ID NO:28 at V_LCDR2, [[and]] SEQ ID NO:30 at V_LCDR3.

Claims 15-22. (Cancelled)

23. (Currently Amended) A pharmaceutical composition comprising the antibody or antibody fragment of ~~Claim 1~~ Claim 12 and a pharmaceutically acceptable carrier.

24. (Currently Amended) A conjugate comprising the antibody or antibody fragment of ~~Claim 1~~ Claim 12 linked to a cytotoxic agent.

25. (Currently Amended) A conjugate comprising the antibody or antibody fragment of ~~Claim 1~~ Claim 12 linked to a label.

26. (Currently Amended) A therapeutic composition effective to inhibit growth of human tumor cells that express IGF-IR, which composition comprises the antibody or antigen binding fragment of ~~Claim 1~~ Claim 12.

27. (Currently Amended) The therapeutic composition of ~~Claim 1~~ Claim 26, which further comprises an antineoplastic agent.

28. (Original) The therapeutic composition of Claim 27, wherein the anti-neoplastic agent is an inhibitor of topoisomerase I or topoisomerase II.

29. (Original) The therapeutic composition of Claim 27, wherein the anti-neoplastic agent is selected from the group consisting of irinotecan, camptothecan, and etoposide.

30. (Currently Amended) A therapeutic composition effective to promote regression of human tumors that express IGF-IR, which composition comprises the antibody or antibody fragment of ~~Claim 1~~ Claim 12.

31. (Original) The therapeutic composition of Claim 30, which further comprises an antineoplastic agent.

32. (Original) The therapeutic composition of Claim 31, wherein the anti-neoplastic agent is an inhibitor of topoisomerase I or topoisomerase II.

33. (Original) The therapeutic composition of Claim 31, wherein the anti-neoplastic agent is selected from the group consisting of irinotecan, camptothecan, or etoposide.

34. (Withdrawn) A method of neutralizing the activation of IGF-LR, which comprises administering to a mammal an effective amount of the antibody or antibody fragment of ~~Claim 1~~ Claim 12.

Claims 35-40. (Cancelled)

41. (Withdrawn) A method of reducing tumor growth which comprises administering to a mammal an effective amount of the antibody or antibody fragment of ~~Claim 1~~ Claim 12.

42. (Withdrawn) The method of Claim 41, which further comprises administering an effective amount of an anti-neoplastic agent.

43. (Withdrawn) The method of Claim 42, wherein the anti-neoplastic agent is an inhibitor of topoisomerase I or topoisomerase II.

44. (Withdrawn) The method of Claim 42, wherein the anti-neoplastic agent is selected from the group consisting of irinotecan, camptothecan, and etoposide.

45. (Withdrawn) A method of promoting tumor regression which comprises administering to a mammal an effective amount of the antibody or antibody fragment of ~~Claim 1~~ Claim 12.

46. (Withdrawn) The method of Claim 45, which further comprises administering an effective amount of an anti-neoplastic agent.

47. (Withdrawn) The method of Claim 46, wherein the anti-neoplastic agent is an inhibitor of topoisomerase I or topoisomerase II.

48. (Withdrawn) The method of Claim 46, wherein the anti-neoplastic agent is selected from the group consisting of irinotecan, camptothecan, and etoposide.

49. (Withdrawn) The method of any one of Claims 41 to 48, wherein the tumor is a breast tumor, colorectal tumor, pancreatic tumor, ovarian tumor, lung tumor, prostate tumor, bone or soft tissue sarcoma or myeloma.

Claims 50-56. (Cancelled)

57. (New) An antibody comprising a heavy chain variable domain represented by SEQ ID NO:2 and a light chain variable domain represented by SEQ ID NO:6.

58. (New) An antibody comprising a heavy chain variable domain represented by SEQ ID NO:2 and a light chain variable domain represented by SEQ ID NO:10.

59. (New): The antibody of Claims 57-58, wherein said antibody has an IgG1 isotype.

60. (New) A pharmaceutical composition comprising the antibody of Claims 57-59 and a pharmaceutically acceptable carrier.